| 120.24 Data as of Jun 18 |  +2.54 / +2.16%Today’s Change | 58.53 Today|||52-Week Range 131.82 | +53.23% Year-to-Date |
| Dividends, Schmividends Jun 18 / MotleyFool.com | Good News for Celgene's Revlimid - Analyst Blog Jun 17 / Zacks.com |
| Good News for Celgene's Pipeline - Analyst Blog Jun 18 / Zacks.com | EC Approves Celgene's REVLIMID as a Treatment for Patients with Rare Form of Blood D... Jun 17 / Benzinga |
| Warning: This Might Be The Most Overvalued Sector In The Market Jun 17 / Street Authority | Threshold Pharmaceuticals: A Biotech That Investors Need To Know About Jun 14 / MotleyFool.com |
| Celgene Corporation (CELG): Today's Featured Health Care Laggard Jun 17 / TheStreet.com | Apremilast Data Presented by Celgene - Analyst Blog Jun 14 / Zacks.com |
| Data on BMY/ AbbVie's elotuzumab - Analyst Blog Jun 17 / Zacks.com | Celgene Announces Statistical Significance for Primary, Secondary Endpoints in Phase ... Jun 14 / Benzinga |
| Previous close | 117.70 |
| Today’s open | 118.28 |
| Day’s range | 117.72 - 120.45 |
| Volume | 1,827,925 |
| Average volume (3 months) | 3,079,011 |
| Market cap | $49.1B |
| Dividend yield | -- |
| Earnings growth (last year) | +15.79% |
| Earnings growth (this year) | +16.49% |
| Earnings growth (next 5 years) | +22.00% |
| Revenue growth (last year) | +12.05% |
| P/E ratio | 36.5 |
| Price/Sales | 6.23 |
| Price/Book | 8.68 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABTAbbott Laboratories | +0.62 | +1.68% |
| LLYEli Lilly and Co | -0.01 | -0.02% |
| AZNAstraZeneca PLC | +0.01 | +0.02% |
| AGNAllergan Inc | +0.01 | +0.01% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | $1.43 |
| Annual revenue (last year) | $5.4B |
| Annual profit (last year) | $1.5B |
| Net profit margin | 26.84% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Robert J. Hugin, MBA |
Chief Operating Officer & Executive Vice President Perry A. Karsen |
Corporate headquarters Summit, New Jersey |
.
